FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022809384> ?p ?o ?g. }

• W2022809384 endingPage "940" @default.
• W2022809384 startingPage "931" @default.
• W2022809384 abstract "Venezuelan equine encephalitis virus replicon particles (VRP) without a transgene (null VRP) have been used to adjuvant effective humoral [1], cellular [2], and mucosal [3] immune responses in mice. To assess the adjuvant activity of null VRP in the context of a licensed inactivated influenza virus vaccine, rhesus monkeys were immunized with Fluzone® alone or Fluzone® mixed with null VRP and then challenged with a human seasonal influenza isolate, A/Memphis/7/2001 (H1N1). Compared to Fluzone® alone, Fluzone® + null VRP immunized animals had stronger influenza-specific CD4+ T cell responses (4.4 fold) with significantly higher levels of virus-specific IFN-γ (7.6 fold) and IL-2 (5.3 fold) producing CD4+ T cells. Fluzone® + null VRP immunized animals also had significantly higher plasma anti-influenza IgG (p < 0.0001, 1.3 log) and IgA (p < 0.05, 1.2 log) levels. In fact, the mean plasma anti-influenza IgG titers after one Fluzone® + null VRP immunization was 1.2 log greater (p < 0.04) than after two immunizations with Fluzone® alone. After virus challenge, only Fluzone® + null VRP immunized monkeys had a significantly lower level of viral replication (p < 0.001) relative to the unimmunized control animals. Although little anti-influenza antibody was detected in the respiratory secretions after immunization, strong anamnestic anti-influenza IgG and IgA responses were present in secretions of the Fluzone® + null VRP immunized monkeys immediately after challenge. There were significant inverse correlations between influenza RNA levels in tracheal lavages and plasma anti-influenza HI and IgG anti-influenza antibody titers prior to challenge. These results demonstrate that null VRP dramatically improve both the immunogenicity and protection elicited by a licensed inactivated influenza vaccine." @default.
• W2022809384 created "2016-06-24" @default.
• W2022809384 creator A5019881240 @default.
• W2022809384 creator A5020519593 @default.
• W2022809384 creator A5033595975 @default.
• W2022809384 creator A5066247793 @default.
• W2022809384 creator A5076952735 @default.
• W2022809384 creator A5079386386 @default.
• W2022809384 creator A5089037138 @default.
• W2022809384 date "2011-01-01" @default.
• W2022809384 modified "2023-09-26" @default.
• W2022809384 title "Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques" @default.
• W2022809384 cites W1551958514 @default.
• W2022809384 cites W1608648792 @default.
• W2022809384 cites W1654759719 @default.
• W2022809384 cites W1752375020 @default.
• W2022809384 cites W1966055810 @default.
• W2022809384 cites W1982615015 @default.
• W2022809384 cites W1985491687 @default.
• W2022809384 cites W1987308851 @default.
• W2022809384 cites W1990123193 @default.
• W2022809384 cites W1992689191 @default.
• W2022809384 cites W1999296669 @default.
• W2022809384 cites W2001285947 @default.
• W2022809384 cites W2005047889 @default.
• W2022809384 cites W2006738527 @default.
• W2022809384 cites W2007799047 @default.
• W2022809384 cites W2009421264 @default.
• W2022809384 cites W2013103459 @default.
• W2022809384 cites W2022787982 @default.
• W2022809384 cites W2024923044 @default.
• W2022809384 cites W2032451916 @default.
• W2022809384 cites W2042249918 @default.
• W2022809384 cites W2052546898 @default.
• W2022809384 cites W2061307630 @default.
• W2022809384 cites W2063339404 @default.
• W2022809384 cites W2065441707 @default.
• W2022809384 cites W2066669003 @default.
• W2022809384 cites W2073234751 @default.
• W2022809384 cites W2084229289 @default.
• W2022809384 cites W2090889765 @default.
• W2022809384 cites W2099739487 @default.
• W2022809384 cites W2113884542 @default.
• W2022809384 cites W2121593344 @default.
• W2022809384 cites W2132665739 @default.
• W2022809384 cites W2144681562 @default.
• W2022809384 cites W2145369044 @default.
• W2022809384 cites W2151846831 @default.
• W2022809384 cites W2157109299 @default.
• W2022809384 cites W2157981287 @default.
• W2022809384 cites W2163092396 @default.
• W2022809384 cites W2164362007 @default.
• W2022809384 cites W79274429 @default.
• W2022809384 cites W2052724339 @default.
• W2022809384 doi "https://doi.org/10.1016/j.vaccine.2010.11.024" @default.
• W2022809384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3026063" @default.
• W2022809384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21111777" @default.
• W2022809384 hasPublicationYear "2011" @default.
• W2022809384 type Work @default.
• W2022809384 sameAs 2022809384 @default.
• W2022809384 citedByCount "32" @default.
• W2022809384 countsByYear W20228093842012 @default.
• W2022809384 countsByYear W20228093842013 @default.
• W2022809384 countsByYear W20228093842014 @default.
• W2022809384 countsByYear W20228093842015 @default.
• W2022809384 countsByYear W20228093842017 @default.
• W2022809384 countsByYear W20228093842018 @default.
• W2022809384 countsByYear W20228093842019 @default.
• W2022809384 countsByYear W20228093842020 @default.
• W2022809384 countsByYear W20228093842022 @default.
• W2022809384 crossrefType "journal-article" @default.
• W2022809384 hasAuthorship W2022809384A5019881240 @default.
• W2022809384 hasAuthorship W2022809384A5020519593 @default.
• W2022809384 hasAuthorship W2022809384A5033595975 @default.
• W2022809384 hasAuthorship W2022809384A5066247793 @default.
• W2022809384 hasAuthorship W2022809384A5076952735 @default.
• W2022809384 hasAuthorship W2022809384A5079386386 @default.
• W2022809384 hasAuthorship W2022809384A5089037138 @default.
• W2022809384 hasBestOaLocation W20228093842 @default.
• W2022809384 hasConcept C159047783 @default.
• W2022809384 hasConcept C159654299 @default.
• W2022809384 hasConcept C203014093 @default.
• W2022809384 hasConcept C22070199 @default.
• W2022809384 hasConcept C2522874641 @default.
• W2022809384 hasConcept C2777546802 @default.
• W2022809384 hasConcept C2777863537 @default.
• W2022809384 hasConcept C2780689484 @default.
• W2022809384 hasConcept C2780868878 @default.
• W2022809384 hasConcept C32611913 @default.
• W2022809384 hasConcept C86803240 @default.
• W2022809384 hasConceptScore W2022809384C159047783 @default.
• W2022809384 hasConceptScore W2022809384C159654299 @default.
• W2022809384 hasConceptScore W2022809384C203014093 @default.
• W2022809384 hasConceptScore W2022809384C22070199 @default.
• W2022809384 hasConceptScore W2022809384C2522874641 @default.
• W2022809384 hasConceptScore W2022809384C2777546802 @default.
• W2022809384 hasConceptScore W2022809384C2777863537 @default.
• W2022809384 hasConceptScore W2022809384C2780689484 @default.

• next